RxDoctor Payments Data

Heather Mixson

Nurse Practitioner · Clearwater, FLNPI 1447296108

Payments from drug & device makers

$17,369in general payments, 2019–2025

Across 578 payments — averaging $30.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$2K
  • AstraZeneca$1K
  • Novartis$1K
  • Incyte Corporation$833
  • Daiichi Sankyo Inc.$751
  • Johnson & Johnson$724
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$16,63896%
  • Education$2321%
  • Other$4993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC32$1,694
AstraZeneca(2 entities)39$1,458
Novartis39$1,215
Incyte Corporation29$833
Daiichi Sankyo Inc.21$751
Johnson & Johnson22$724
Sanofi24$691
Myriad Genetic Laboratories, Inc.8$689
Eisai Inc.18$579
Merck24$572
Rigel Pharmaceuticals, Inc.15$523
Karyopharm Therapeutics Inc.7$444
Gilead(2 entities)18$435
GSK9$365
Seagen Inc.20$351
Astellas Pharma US Inc16$294
AbbVie12$279
Pfizer13$277
Takeda Pharmaceuticals U.S.A., Inc.11$268
Pharmacyclics LLC, An Abbvie Company7$260
Ipsen Biopharmaceuticals, Inc5$255
Regeneron Healthcare Solutions, Inc.9$238
Bayer12$234
E.r. Squibb & Sons, L.L.C.12$227
Array Biopharma Inc9$186
Amgen10$181
Servier Pharmaceuticals LLC4$177
CSL Behring8$173
Blueprint Medicines Corporation5$163
Pharmaessentia USA Corporation6$152
Astellas Pharma Global Development1$125
Foundation Medicine, Inc.2$122
AVEO Pharmaceuticals, Inc.7$122
Sanofi US Services Inc.1$121
Bristol Myers Squibb5$114
Pharmacosmos Therapeutics Inc.5$111
Genentech USA, Inc.6$107
Puma Biotechnology, Inc.5$105
Jazz Pharmaceuticals Inc.5$101
Sobi, Inc5$99
Sumitomo Pharma America, Inc.5$98
Stemline Therapeutics Inc.4$98
CTI Biopharma Corp.2$92
Morphosys, US Inc.2$85
Dendreon Pharmaceuticals LLC3$84
Tersera Therapeutics LLC3$81
Taiho Oncology, Inc.4$69
Deciphera Pharmaceuticals Inc.4$69
Myovant Sciences Inc.4$69
Genmab U.S., Inc.2$58
Exelixis Inc.3$57
Kyowa Kirin, Inc.3$54
Geron Corporation2$52
EMD Serono, Inc.2$45
Mirati Therapeutics, Inc.2$45
Boehringer Ingelheim2$41
Legend Biotech USA Inc.1$36
Dova Pharmaceuticals2$33
Recordati_rare_diseases_inc.1$32
Sun Pharmaceutical Industries Inc.2$30

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,369 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$2,450
Medicare patients
26
Services billed
29

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FotivdaTivozanib Hcl13$395,238
BrukinsaZanubrutinib21$310,599
TasignaNilotinib Hcl12$235,186
VenclextaVenetoclax23$157,913
EliquisApixaban43$36,617
XareltoRivaroxaban29$32,166
Tamoxifen Citrate68$2,208
Ondansetron OdtOndansetron50$1,464
Anastrozole42$1,131
Letrozole32$1,059
Prochlorperazine Maleate48$862
Dexamethasone22$770
Hydroxyurea34$764
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim11$507
Levothyroxine Sodium45$506

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisTasigna$1,215$235,18612 claims
AbbVieVenclexta$279$157,91323 claims
PfizerEliquis$277$36,61743 claims
Johnson & JohnsonXarelto$724$32,16629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →